MARKET

SONN

SONN

Sonnet Biotherapeutc Hldng Inc
NASDAQ
2.552
-0.058
-2.24%
Opening 10:35 12/03 EST
OPEN
2.620
PREV CLOSE
2.610
HIGH
2.705
LOW
2.552
VOLUME
16.57K
TURNOVER
--
52 WEEK HIGH
18.72
52 WEEK LOW
2.500
MARKET CAP
2.14M
P/E (TTM)
-0.1056
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SONN last week (1125-1129)?
Weekly Report · 1d ago
Weekly Report: what happened at SONN last week (1118-1122)?
Weekly Report · 11/25 12:12
Weekly Report: what happened at SONN last week (1111-1115)?
Weekly Report · 11/18 12:08
Warning: SONN is at high risk of performing badly
Seeking Alpha · 11/13 13:35
Sonnet BioTherapeutics releases ‘What this Means’ segment
TipRanks · 11/12 14:31
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Barchart · 11/12 08:15
Weekly Report: what happened at SONN last week (1104-1108)?
Weekly Report · 11/11 12:28
Sonnet BioTherapeutics prices $5M at-the-market offering
TipRanks · 11/06 18:25
More
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Webull offers Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ: SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.